依达拉奉右莰醇联合丁苯酞治疗对老年大动脉粥样硬化型脑卒中患者血清PTX3、lp-PLA2以及MES的影响  

Effects of Edaravone Dexborneol Combined with Butylphthalideon Serum PTX3, lp-PLA2 and MES in Elderly Patients

作　　者：景燕[1] 王泽斌[1] 曾姗 陆明佳[1] 仲婷[1] 李红燕[1] JING Yan;WANG Ze-bin;ZENG Shan;LU Ming-jia;ZHONG Ting;LI Hong-yan(Department of Neurology,People's Hospital of Xinjiang Uygur Autonomous Region,Xinjiang Clinical Research Center for Stroke and Neurological Rare Disease,Urumqi,Xinjiang,830001,China)

机构地区：[1]新疆维吾尔自治区人民医院神经内科新疆脑卒中与神经系统罕见病临床医学研究中心,新疆乌鲁木齐830001

出　　处：《现代生物医学进展》2023年第12期2392-2395,2400,共5页Progress in Modern Biomedicine

基　　金：新疆维吾尔自治区自然科学基金项目(2020D01C196)。

摘　　要：目的:探讨依达拉奉右莰醇联合丁苯酞对老年大动脉粥样硬化(LAA)型脑卒中患者血清五聚素3(PTX3)、脂蛋白相关磷脂酶A2(Lp-PLA2)以及微栓子信号(MES)的影响。方法:回顾性选取2021年9月-2022年9月在本院收治的120例老年LAA型脑卒中患者,根据其不同治疗方案分为对照组(56例),采用依达拉奉右莰醇单独治疗,和观察组(64例),采用依达拉奉右莰醇联合丁苯酞治疗。观察两组患者的临床疗效;对比两组患者治疗前后神经功能[脑卒中量表(NIHSS)及中枢神经特异性蛋白(S-100β)、神经元特异性烯醇化酶(NSE)]状态、炎症因子[血清五聚素3(PTX3)、脂蛋白相关磷脂酶A2(Lp-PLA2)]水平及脑血流微栓子信号(MES)阳性率变化。记录不良反应发生情况。结果:观察组患者治疗有效率为95.31%,高于对照组的78.57%(χ^(2)=7.653,P=0.006);治疗后,观察组患者NIHSS评分、S-100β及NSE水平低于对照组(P<0.05);观察组PTX3、Lp-PLA2水平及MES阳性率低于对照组(P<0.05)。观察组与对照组总不良反应发生率比较无差异(6.25%vs 5.36%)(Fisher=1.000)。结论:依达拉奉右莰醇联合丁苯酞可有效提高临床疗效,促进老年LAA型患者神经功能恢复,降低PTX3、lp-PLA2水平及MES阳性率,控制病情发展,且安全性较好。Objective:To investigate the effects of edaravone dexborneol combined with butylphthalide on serum pentraxin 3(PTX3),lipoprotein associated phospholipase A2(lp-PLA2)and microembolic signals(MES)in elderly patients with large artery atherosclerosis(LAA)stroke.Methods:A total of 120 elderly patients with LAA and stroke admitted to the hospital were retrospectively enrolled between September 2021 and September 2022.According to different treatment methods,they were divided into control group(56 cases,edaravone dexborneol)and observation group(64 cases,edaravone dexborneol combined with butylphthalide).The clinical curative effect in both groups was observed.The changes in nerve function[National Institutes of Health Stroke Scale(NIHSS),central nervous system-specific protein(S-100β),neuron-specific enolase(NSE)],inflammation factors(PTX3,lp-PLA2)and positive rate of MES before and after treatment were compared between the two groups.The occurrence of adverse reactions was recorded.Results:The response rate of treatment in observation group was higher than that in control group(95.31%vs 78.57%)(χ^(2)=7.653,P=0.006).After treatment,NIHSS score,S-100βand NSE levels in observation group were lower than those in control group(P<0.05),levels of PTX3 and lp-PLA2,and positive rate of MES were lower than those in control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between observation group and control group(6.25%vs 5.36%)(Fisher=1.000).Conclusion:Edaravone dexborneol combined with butylphthalide can effectively improve the clinical efficacy,promote the recovery of neurological function,reduce the levels of PTX3,lp-PLA2 and the positive rate of MES in elderly patients with LAA,and control the development of the disease,with good safety.

关 键 词：依达拉奉右莰醇 丁苯酞 老年脑卒中 大动脉粥样硬化型 神经功能 五聚素3 脂蛋白相关磷脂酶A2 微栓子信号 

分 类 号：R743.3[医药卫生—神经病学与精神病学]